Zandelisib

Zandelisib
Legal status
Legal status
  • Investigational
Identifiers
  • 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC31H38F2N8O
Molar mass576.697 g·mol−1
3D model (JSmol)
  • CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F
  • InChI=1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)
  • Key:WPFUFWIHMYZXSF-UHFFFAOYSA-N

Zandelisib is an investigational new drug that is being evaluated to treat follicular lymphoma.[1] It is a phosphatidylinositol 3 kinase delta inhibitor.[2]

References

  1. ^ "Zandelisib - MEI Pharma/Kyowa Kirin". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Hus I, Puła B, Robak T (March 2022). "PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives". Cancers. 14 (6): 1571. doi:10.3390/cancers14061571. PMC 8945984. PMID 35326722.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.